Search

everythinglearnresearchcommunity

for

Search:↓

Researchers found three different ways drugs work to treat hair loss from alopecia areata and identified key factors for personalized treatment.

New treatments for alopecia areata may target specific immune cells and pathways involved in hair loss.

CD8+ T cells attack hair follicle stem cells, causing scarring and hair loss.

Educating primary care doctors and improving referrals to rheumatologists can reduce delays in treating lupus patients.

Stem cells and their secretions could potentially treat stress-induced hair loss, but more human trials are needed.

MS patients often have skin issues, so regular skin checks are important.

JAK inhibitors, like baricitinib, are effective and safe for treating alopecia areata.

Simvastatin/ezetimibe may help treat new cases of alopecia areata but not long-term cases.

A 9-year-old girl developed type 1 diabetes and alopecia after being treated for a rare kidney disease.

Dermal Papilla Cells grown in 3D and with stem cells better mimic natural hair growth conditions than cells grown in 2D.

The document concludes that more research is needed to better understand and treat primary cicatricial alopecias, and suggests a possible reclassification based on molecular pathways.

Dupilumab can help hair regrowth but may also trigger alopecia areata.

miR-199a-3p controls hair growth and is linked to alopecia areata.

Dendrobium officinale polysaccharide helps hair growth by activating the WNT signaling pathway.

Targeting IL-17 could help treat pattern hair loss.

Vitamin A affects hair loss and immune response in alopecia areata.

Microneedle patches improve drug delivery for skin treatments and cosmetic enhancements.

The cause of Frontal fibrosing alopecia, a type of hair loss, is complex, likely involving immune responses and genetics, but is not fully understood.

Blocking JAK1 or JAK3 helps reverse hair loss in a mouse model of alopecia areata.

After severe COVID-19, 71% of patients experienced excessive hair shedding and thinning within 3 months due to factors like low oxygen levels, medication, stress, and autoimmune disease.

New therapies are being developed that target integrin pathways to treat various diseases.

Apremilast was not effective in treating moderate-to-severe alopecia areata.

The JAK/STAT pathway is important in cell processes and disease, and JAK inhibitors are promising for treating related conditions.

JAK inhibitors can effectively reverse hair loss in people with alopecia areata.

Upadacitinib and narrowband UVB effectively treated a child's vitiligo and alopecia areata.

Current treatments for Alopecia Areata have mixed success, and there's a need for better, more accessible options and support for affected individuals.

BIVV009 is a safe treatment for bullous pemphigoid that reduces C3 deposition without harmful side effects.

Understanding how cells die in the skin is important for treating skin diseases and preventing hair loss.

More research is needed to understand the genetic causes of Alopecia areata to develop better treatments.

Baricitinib is a promising treatment for severe alopecia areata with minimal side effects.